FDA Adds Boxed Warning to Injectafer for Risk of Symptomatic Hypophosphatemia
核心洞察
The FDA approved labeling revisions adding a boxed warning—its strongest safety warning—to ferric carboxymaltose injection (Injectafer) describing the risk of symptomatic hypophosphatemia (搜索).
The warning recommends serum phosphate monitoring in at-risk patients and in anyone receiving a repeat course within three months of a prior course.
FDA's Sentinel System data show serum phosphate testing occurs in fewer than 20% of ferric carboxymaltose administration episodes, despite earlier label changes in 2020 and 2023.
The Food and Drug Administration (搜索) has placed its most prominent safety warning on ferric carboxymaltose injection, sold as Injectafer, one of the most widely used intravenous iron treatments in the United States. The agency approved labeling revisions adding a boxed warning describing the risk of symptomatic hypophosphatemia (搜索)—dangerously low levels of phosphate in the blood—and recommending phosphate monitoring in patients at risk and in any patient receiving a repeat course of therapy within three months of the prior course.
The action affects a drug administered in outpatient infusion suites, hematology clinics, cardiology offices, and hospital day units nationwide. Injectafer is approved for iron deficiency anemia (搜索) in patients one year of age and older who cannot tolerate oral iron or do not fully respond to it, for iron deficiency in adults with non-dialysis-dependent chronic kidney disease (搜索), and for iron deficiency in adults with heart failure (搜索) classified as New York Heart Association class II or III to improve exercise capacity.
A Warning That Moves to the Top of the Label
A boxed warning is the strongest labeling requirement the FDA can impose short of pulling a product. In its drug safety communication, the agency said clinical effects depend on how severe and how prolonged the phosphate drop is. Reported symptoms include muscle weakness or pain, fatigue, tremors, confusion, seizures, and cardiac arrhythmias. Chronic severe hypophosphatemia (搜索) can lead to osteomalacia (搜索), a softening of bone, and to fractures.
This is not the agency's first action on the issue. The FDA determined in 2019 that the drug can cause serious symptomatic hypophosphatemia (搜索), and a warning was added in February 2020. In May 2023, that warning was revised to add phosphate monitoring recommendations, to name osteomalacia (搜索) and fractures as possible long-term complications, and to list inflammatory bowel disease (搜索) as a risk factor. The warning was revised again in 2025 to add further risk factors, and those layers are reflected in the current prescribing information.
The latest escalation followed a fresh agency assessment drawing on adverse event reports, published literature, and the FDA's Sentinel System. Regulators concluded that symptomatic hypophosphatemia (搜索) was still being reported despite the earlier label changes. The safety communication was published on September 1.
Patients Most Likely to Be Affected
Risk is not spread evenly. The people most exposed are those receiving repeat courses, particularly a second course within three months, and those with conditions that already predispose them to phosphate loss. The manufacturer's safety information lists possible risk factors including gastrointestinal disorders associated with malabsorption, inflammatory bowel disease (搜索), hyperparathyroidism, vitamin D deficiency, malnutrition, and hereditary hemorrhagic telangiectasia.
Iron deficiency anemia (搜索) itself is common in groups that already carry other health burdens, affecting many patients with gastrointestinal disease, people with chronic kidney disease (搜索), patients with heart failure (搜索), and women with heavy uterine bleeding or postpartum anemia. Because Injectafer is approved down to age one, pediatric patients are also covered by the new labeling.
There is a confounding detail that matters at the bedside. The FDA noted that some symptoms of low phosphate can resemble the symptoms of iron deficiency anemia (搜索) itself, with fatigue and weakness as the obvious overlap. A patient who feels worn out after an infusion may reasonably assume the anemia has not improved yet, when the cause could be something else entirely.
The Monitoring Gap Behind the Decision
The most striking figure in the agency's assessment is not about the drug but about follow-up. Data from the FDA's Sentinel System indicate that serum phosphate laboratory testing occurs in fewer than 20 percent of ferric carboxymaltose administration episodes. That means the recommended safety check was skipped in the large majority of infusions, seven years after the agency first determined the risk was real and three years after monitoring language was written into the label.
The FDA said the adverse event case series included reports following both single and multiple infusions, and that consequences included hospitalization, phosphate replacement therapy lasting weeks to months, and extensive monitoring with regular follow-up visits. The agency's own framing is that this harm is largely preventable, writing that the adverse reaction can be prevented or reduced in severity through appropriate phosphate monitoring and early intervention, and that the boxed warning highlights guidance already present in the labeling.
Certain strengths of the drug are also sold as generic ferric carboxymaltose. Generic application holders are expected to update their own labeling to match.
Clinical Recommendations
The FDA advises patients to immediately report new or worsening symptoms of low phosphate to a health care professional, naming muscle weakness or pain, fatigue, bone and joint pain, and confusion. Anyone experiencing seizures, an irregular heartbeat, chest pain, or a sudden change in alertness should seek urgent medical care.
For clinicians, the agency recommends checking serum phosphate levels prior to a repeat course of treatment if the patient is at risk for low serum phosphate or will receive a repeat course within three months of the prior course, correcting pre-existing hypophosphatemia (搜索) prior to administering Injectafer, monitoring serum phosphate levels in patients at risk for chronic low serum phosphate, treating hypophosphatemia as medically indicated, and considering permanent discontinuation of Injectafer for severe symptomatic or persistent hypophosphatemia.
Patients should not stop or delay treatment on their own. Iron deficiency anemia (搜索) has real consequences, and this labeling change is about monitoring rather than withdrawal. Patients and clinicians can report problems through the FDA MedWatch program.
What remains unresolved is how quickly infusion practice will change. The FDA has not published a target monitoring rate, and no timeline has been announced for reassessing whether testing improves.